Literature DB >> 9653895

Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.

M Alegret1, J C Verd, C Díaz, G Hernández, T Adzet, R M Sánchez, J C Laguna.   

Abstract

The effect of atorvastatin (3 mg kg(-1) day(-1)), simvastatin (3 mg kg(-1) day(-1)) and bezafibrate (100 mg kg(-1) day(-1)) administered for 4 weeks to male New Zealand white rabbits on enzyme activities related to lipid metabolism has been studied. Only the statins reduced plasma cholesterol values, while none of the drugs modified plasma triglyceride or high density lipoprotein (HDL)-cholesterol concentrations, nor the activity of enzymes such as hepatic diacylglycerol acyltransferase, lipoprotein lipase or hepatic lipase, directly involved in triglyceride metabolism. Both statins elicited similar increases in the hepatic microsomal 3-hydroxy-3-methyl-glutaryl Coenzyme A (CoA) reductase activity (147 and 109% induction for simvastatin and atorvastatin, respectively), and none of the drugs assayed modified hepatic acyl-coenzyme A:cholesterol acyltransferase activity significantly. Only bezafibrate induced a significant 57% reduction in the activity of hepatic microsomal cholesterol 7alpha-hydroxylase. Regarding the rate limiting enzyme of phosphatidylcholine biosynthesis, CTP:phosphocholine cytidylyl transferase, atorvastatin and bezafibrate behaved similarly, decreasing the enzyme activity in the liver by 45% and 54%, respectively; simvastatin induced no modification of this activity. The reduction of CTP:phosphocholine cytidylyl transferase activity is not caused by a direct inhibition of the enzyme by bezafibrate and atorvastatin. Further, the inhibitory effect of atorvastatin appears to be unrelated to the inhibition of 3-hydroxy-3-methyl-glutaryl CoA reductase elicited in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9653895     DOI: 10.1016/s0014-2999(98)00096-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.

Authors:  J C Verd; C Peris; M Alegret; C Díaz; G Hernández; M Vázquez; T Adzet; J C Laguna; R M Sánchez
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

Authors:  B R Ito; B-H Zhang; E E Cable; X Song; J M Fujitaki; D A MacKenna; C E Wilker; B Chi; P D van Poelje; D L Linemeyer; M D Erion
Journal:  Br J Pharmacol       Date:  2009-01-22       Impact factor: 8.739

3.  High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.

Authors:  Núria Roglans; Joan C Verd; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

4.  Lovastatin reversed the enhanced sphingomyelin caused by 27-hydroxycholesterol in cultured vascular endothelial cells.

Authors:  Qi Zhou; Allan Luo; Fred A Kummerow
Journal:  Biochem Biophys Rep       Date:  2015-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.